- Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab’s differentiated effects of targeting IL-13R vs IL-4R
- Using an established COPD model of human lung slices, new data demonstrate eblasakimab’s potential to reduce airway constriction and enhance dilation
- Results demonstrate for the first time the potential utility of eblasakimab in other indications beyond AD
San Mateo, California, and Singapore, November 3, 2023 – ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced new data was presented at the Dermatology Drug Development Summit (DDDS) that took place in Boston, MA, from October 31 to November 2, 2023. The datasets presented strengthen evidence for eblasakimab’s differentiated mechanism of action in atopic dermatitis (AD), and, for the first time, show application in a new indication, chronic obstructive pulmonary disease (COPD), which can be driven by Type 2 inflammation.
For more information, please refer to the press release.